• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

作者信息

Ma Wanlong, Kantarjian Hagop, Yeh Chen-Hsiung, Zhang Zhong J, Cortes Jorge, Albitar Maher

机构信息

Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92675, USA.

出版信息

Acta Haematol. 2009;121(1):27-31. doi: 10.1159/000210060. Epub 2009 Mar 31.

DOI:10.1159/000210060
PMID:19332983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2790522/
Abstract
摘要

相似文献

1
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.由于过早的翻译终止导致的BCR-ABL截短作为对激酶抑制剂耐药的一种机制。
Acta Haematol. 2009;121(1):27-31. doi: 10.1159/000210060. Epub 2009 Mar 31.
2
Chronic myelogenous leukemia. Preface.慢性粒细胞白血病。前言。
Hematol Oncol Clin North Am. 2011 Oct;25(5):ix-x. doi: 10.1016/j.hoc.2011.10.001.
3
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?慢性粒细胞白血病对酪氨酸激酶抑制剂的耐药性：实验室如何判定？
Lab Hematol. 2004;10(3):181-4.
4
BCR-ABL in chronic myelogenous leukemia--how does it work?慢性粒细胞白血病中的BCR-ABL——它是如何起作用的？
Acta Haematol. 2008;119(4):212-7. doi: 10.1159/000140633. Epub 2008 Jun 20.
5
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.泛 BCR-ABL 抑制剂 ponatinib（AP24534）的结构机制：克服激酶抑制剂耐药性的经验教训。
Chem Biol Drug Des. 2011 Jan;77(1):1-11. doi: 10.1111/j.1747-0285.2010.01054.x. Epub 2010 Nov 30.
6
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.在二代酪氨酸激酶抑制剂时代，费城染色体阳性白血病患者中 BCR-ABL 突变的全景。
Hematol Oncol. 2020 Aug;38(3):390-398. doi: 10.1002/hon.2721. Epub 2020 Feb 24.
7
Mutant BCR-ABL clones in chronic myeloid leukemia.慢性髓性白血病中的突变型BCR-ABL克隆
Haematologica. 2011 Mar;96(3):347-9. doi: 10.3324/haematol.2010.039560.
8
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.BCR-ABL TKIs 耐药机制及治疗策略：综述。
Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13.
9
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.慢性髓性白血病中的新型Bcr-Abl抑制剂：控制耐药性
Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.
10
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.费城染色体阳性白血病患者对达沙替尼的耐药性以及BCR-ABL激酶结构域中315和317位残基处突变的存在或选择。
Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822.

引用本文的文献

1
Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia.人类遗传学对用于治疗慢性髓性白血病的酪氨酸激酶抑制剂疗效影响的研究进展
Cureus. 2024 Mar 20;16(3):e56545. doi: 10.7759/cureus.56545. eCollection 2024 Mar.
2
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.2 例伴有费城染色体阳性 B 细胞前体急性淋巴细胞白血病的 ABL1 截断突变病例报告。
Int J Hematol. 2024 Feb;119(2):205-209. doi: 10.1007/s12185-023-03691-y. Epub 2024 Jan 18.
3
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.在患有慢性髓性白血病的对伊马替尼耐药的埃塞俄比亚患者中，BCR-ABL 突变谱和治疗结果。
JCO Glob Oncol. 2021 Jul;7:1187-1193. doi: 10.1200/GO.21.00058.
4
Tyrosine kinase inhibitors induce alternative spliced BCR-ABL variant via inhibition of RNA polymerase II on genomic BCR-ABL.酪氨酸激酶抑制剂通过抑制基因组 BCR-ABL 上的 RNA 聚合酶 II 诱导 BCR-ABL 变体的剪接。
Cancer Sci. 2020 Jul;111(7):2361-2373. doi: 10.1111/cas.14424. Epub 2020 Jun 14.
5
Fusion transcripts: Unexploited vulnerabilities in cancer?融合转录本：癌症未被开发的弱点？
Wiley Interdiscip Rev RNA. 2020 Jan;11(1):e1562. doi: 10.1002/wrna.1562. Epub 2019 Aug 13.
6
Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.联合治疗治疗晚期耐药性急性淋巴细胞白血病。
Cancer Immunol Res. 2019 Jul;7(7):1106-1119. doi: 10.1158/2326-6066.CIR-19-0058. Epub 2019 May 28.
7
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.新型 BCR-ABL 激酶区基因突变导致慢性髓性白血病患者对伊马替尼耐药。
Sci Rep. 2019 Feb 20;9(1):2412. doi: 10.1038/s41598-019-38672-x.
8
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.持续检测到剪接变异的BCR-ABL会导致无法实现深度分子反应。
Cancer Sci. 2017 Nov;108(11):2204-2212. doi: 10.1111/cas.13353. Epub 2017 Sep 21.
9
It Is Imperative to Establish a Pellucid Definition of Chimeric RNA and to Clear Up a Lot of Confusion in the Relevant Research.有必要对嵌合 RNA 进行清晰的定义，并澄清相关研究中的许多混淆。
Int J Mol Sci. 2017 Mar 28;18(4):714. doi: 10.3390/ijms18040714.
10
Hypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random Primers.假设：连续逆转录和内源性随机引物导致的假象，包括具有短同源序列的假嵌合RNA。
J Cancer. 2015 May 1;6(6):555-67. doi: 10.7150/jca.11997. eCollection 2015.

本文引用的文献

1
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.慢性髓性白血病患者BCR-ABL缺失突变体的特征分析
Leukemia. 2008 Jun;22(6):1184-90. doi: 10.1038/leu.2008.65. Epub 2008 Mar 20.
2
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.接受激酶抑制剂治疗的慢性髓性白血病患者中，BCR-ABL激酶结构域存在内含子衍生的插入/截断突变。
J Mol Diagn. 2008 Mar;10(2):177-80. doi: 10.2353/jmoldx.2008.070128. Epub 2008 Feb 14.
3
Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.费城染色体阳性白血病中的替代性BCR/ABL剪接变体可产生新的肿瘤特异性融合蛋白，这些蛋白可能是免疫治疗方法的潜在靶点。
Cancer Res. 2007 Jun 1;67(11):5300-7. doi: 10.1158/0008-5472.CAN-06-3737.
4
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.接受伊马替尼治疗的慢性髓性白血病患者的五年随访
N Engl J Med. 2006 Dec 7;355(23):2408-17. doi: 10.1056/NEJMoa062867.
5
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.达沙替尼在伊马替尼治疗失败后的慢性期慢性髓性白血病中可诱导显著的血液学和细胞遗传学反应。
Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30.
6
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.
7
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.Src在实体瘤和血液系统恶性肿瘤中的作用：新一代Src抑制剂的研发
Cancer. 2006 Oct 15;107(8):1918-29. doi: 10.1002/cncr.22215.
8
Circumventing resistance to kinase-inhibitor therapy.规避对激酶抑制剂疗法的耐药性。
N Engl J Med. 2006 Jun 15;354(24):2594-6. doi: 10.1056/NEJMe068073.
9
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.尼洛替尼用于伊马替尼耐药的慢性粒细胞白血病和费城染色体阳性的急性淋巴细胞白血病。
N Engl J Med. 2006 Jun 15;354(24):2542-51. doi: 10.1056/NEJMoa055104.
10
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.